ECTRIMS2023

ECTRIMS 2023: NMOSD disability progresses faster than in MOGAD

People with neuromyelitis optica spectrum disorder (NMOSD) experience faster disability progression with fewer attacks than those with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a related condition, according to a long-term analysis of German registry data. Notably, in all patients, experiencing inflammation in the optic nerve, which transmits signals between…

ECTRIMS 2023: Early, nonspecific symptoms may precede 1st attack

Nearly 1 in 5 people with neuromyelitis optica spectrum disorder (NMOSD) experience early neurological symptoms prior to their first established NMOSD attack, new research suggests. These symptoms could represent an NMOSD prodrome, a disease stage where nonspecific symptoms emerge before the classic manifestations of the disease. A better…